LEADS BIOLABS-B (09887) News

Nanjing Leads Biolabs Co., Ltd. Class H (9887) Receives a Buy From Shenwan Hongyuan

TipRanksSep 11 17:16

LEADS BIOLABS-B(09887.HK):Differentiated Technology Platforms Create Innovation Moat With Accelerating FIC/BIC Pipeline

Founded in 2012, Leads Biolabs was a clinical-stage biotechnology company focuse

Sep 10 21:22

WeLide-B (9887.HK): LBL-024 Enters Listing Process; Clinical Asset Portfolio Gradually Expands

Event: The company announced its 2026 interim report. Revenue for the first half of 2026 amounted to RMB 36 million (nil in the first half of 2025), primarily derived from milestone payments under the licensing agreement with Dianthus for LBL-047. The loss for the period was

China Post SecuritiesSep 4 20:12

CLSA: Fundamentals of China’s biotechnology sector remain solid; top picks include BeiGene (06160.HK), Innovent Bio (01801.HK), and Vellbio (09887.HK)

Lyondell issued a report stating that the fundamentals of China’s biotechnology sector remain solid, supported by strong interim results, sustained momentum in out-licensing deals, and encouraging clinical data readouts. However, market sentiment has not yet fully reflected these fundamental improvements; the bank attributes this gap primarily to liquidity factors rather than a weakening of fundamentals. The bank believes that high-quality biotech companies with attractive valuations will remain advantaged once sentiment normalizes, and maintains BeiGene (06160.HK), Innovent Bio (01801.HK), and VelosBio-B (09887.HK) as its top picks in the Chinese biotechnology sector. The bank noted that in the first half of 2026,

AASTOCKSSep 4 13:29

SDIC Securities Keeps Their Buy Rating on Nanjing Leads Biolabs Co., Ltd. Class H (9887)

TipRanksSep 4 13:06

The total market value of shares deposited for Weilizhibo-B (09887) amounts to HK$669 million, with shareholders depositing 9.7137 million shares into Morgan Stanley Hong Kong Securities.

On September 3, Weilizhibo-B (09887) experienced unusual movements in its securities positions. The total market value of deposited shares amounted to HK$669 million, representing 5.05% of the float. Shareholders of the company deposited 9.7137 million shares with Morgan Stanley Hong Kong Securities, increasing their shareholding ratio by 4.92 percentage points.

Zhitong FinanceSep 4 08:34

Shanghai Hankang Private Equity Fund Management Co., Ltd. reduced its stake in WeLisBi-B (09887.HK) by 2.846 million shares at approximately HK$65.35 per share.

On September 2, Shanghai Hankang Private Equity Fund Management Co., Ltd. reduced its stake in WeLishengbo-B (09887) by 2.846 million shares at a price of HK$65.3481 per share, for a total consideration of approximately HK$186 million.

Zhitong FinanceSep 3 19:16

Weilishibo-B (09887.HK): Core PD-L1/4-1BB bispecific antibody program advancing smoothly; next-generation immuno-oncology backbone drug shows promise

Event: The company announced its interim results for 2026, reporting operating revenue of RMB 36 million, compared to zero in the same period last year; net profit attributable to shareholders was a loss of RMB 222 million. Core product: PD-L1/4-1BB bispecific antibody LBL-02.

SDIC SecuritiesSep 3 18:51

Morgan Stanley raises Lixiang Auto's (09887.HK) target price to HK$85, maintaining a "Market Perform" rating

Morgan Stanley issued a report stating that it has incorporated the first-line non-small cell lung cancer (NSCLC) indication for LBL-024 (PD-L1/4-1BB) into its model for VelisBio (09887.HK). This adjustment follows the release of abstracts at the World Conference on Lung Cancer (WCLC), which showed positive objective response rate (ORR) data in a larger sample size, and takes into account the upcoming durability data to be presented at the WCLC in mid-September. The bank applies a conservative 20% probability of success assumption for this indication in China and assumes that, if successful, commercial launch will occur after 2030. Meanwhile, the potential of LBL-024 has not yet been included in the base-case scenario.

AASTOCKSSep 3 11:23

Major Brokerage: CLSA Raises Wellbiome (09887.HK) Target Price to HK$116.9; LBL-024 Data Imminent

CLSA issued a research report stating that Wellbiome’s (09887.HK) partnership revenue in the first half of the year amounted to RMB 36 million, while its net loss for the period widened by 33.4% year-on-year to RMB 222 million. The bank identified key catalysts including updated data on LBL-024 for first-line non-small cell lung cancer (NSCLC), which will be presented as an oral report at the 2026 World Conference on Lung Cancer (WCLC) to be held this month. The company indicated that Phase III clinical trials of LBL-024 for first-line NSCLC are scheduled to commence in 2027, and it has been actively seeking global partners since last month. The bank raised

AASTOCKSSep 2 13:03

Nanjing Leads Biolabs Advances Next-Generation Immuno-Oncology Pipeline Toward First-in-Class Approval

TipRanksAug 31 17:50

Weilizhibo-B (09887.HK) reported H1 revenue of RMB 36 million and a loss of RMB 221.9 million for the period.

Gelonghui, August 31 — Wellist Biologics-B (09887.HK) announced its interim results. For the six months ended June 30, 2026, the net loss increased by RMB 55.5 million, or 33.4%, to RMB 221.9 million from RMB 166.4 million in the corresponding period. Revenue rose from nil to RMB 36.0 million, derived entirely from a licensing agreement with Dianthus Therapeutics for LBL-047. This amount includes USD 5 million in licensing revenue recognized upon achieving the Phase I clinical trial milestone in China.

Gelonghui FinanceAug 31 16:35

LEADS BIOLABS-B: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026

HKEXAug 31 16:30

Zhitong Stock Connect: Statistics on Abnormal Changes in Shareholding Proportions | August 31

Zhitong Statistics on Significant Changes in Southbound Trading Proportions | August 28, 2026

Zhitong FinanceAug 31 08:36

Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Phase II Clinical Study for First-Line Treatment of Esophageal Squamous Cell Carcinoma Advances to Expansion Stage

NANJING, China, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that Opamtistomig (LBL-024), the Company's

GlobeNewswireAug 25 10:25

Hong Kong Stocks in Focus | Weili Zhibo-B (09887) rises over 5% in early trading as Phase II clinical study of Weilisun for first-line treatment of ESCC enters expansion phase

Weili Zhibo-B (09887) rose more than 5% in early trading. As of press time, the stock was up 4.42% at HK$72.1, with a turnover of HK$33.5464 million.

Zhitong FinanceAug 25 10:08

HK Stock Announcements Spotlight | Leapmotor Releases Interim Results; Profit Attributable to Shareholders Reaches RMB 208 Million, Up 530.97% Year-on-Year

Yunyinggu Technology (03310) announced its interim results, reporting revenue of RMB 318 million, while deepening its presence in the brand AMOLED display driver IC market. HeYu-B (02256) successfully commercialized its core drug, Bejiemai, in the first half of the year, with continued increases in R&D expenditure.

Zhitong FinanceAug 25 09:11

HK Stock Announcements Watch | Aim Vaccine releases interim results with revenue of RMB 351 million; will continue to accelerate the commercialization and market预热 (pre-heating) of key products, including its next-generation rabies vaccine series.

Aim Vaccine (06660): Marketing authorization application submitted for iteratively improved high-potency human diploid cell rabies vaccine; Alibaba-W (09988) plans to place new shares in Hong Kong, with total placement consideration of HK$80 billion

Zhitong FinanceAug 24 09:13

Nanjing Leads Biolabs Co., Ltd. Class H (9887) Gets a Buy From Shenwan Hongyuan

TipRanksAug 22 13:16

Following the commercial launch of mRNA cancer vaccines, which innovative drug sectors are poised for a "GPT moment"?

1. mRNA technology has made its first breakthrough from preventive vaccines into the field of oncology treatment, with brokerage firms hailing it as the "GPT moment" for cancer vaccines; 2. The 2026 WCLC and ESMO annual congresses will be held in Seoul, South Korea, and Madrid, Spain, respectively; 3. It is reported that three ADCs will be featured in late-breaking abstract oral presentations at the WCLC congress, while second-generation immuno-oncology (IO) therapies are also expected to gain significant visibility.

cls.cnAug 22 11:14